Budillon A. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate.
Meet the Editorial Board
Recent Patents on Anti-Cancer Drug Discovery, 2015, Vol. 10, No. 1
1
Meet the Editorial Board Alfredo Budillon Dr. Alfredo Budillon graduated in Medicine in 1989 and obtained the PhD, in Oncology, in 1995 and Specialty Board Certification in Oncology, in 1997. He has a Masters degree in Health Economy, Management and Bioethics. He gained experience in Biochemistry and antitumor experimental therapeutics field during a stage as Fogarty Visiting Fellow at the Cellular Biochemistry Section, National Cancer Institute, NIH, directed by Dr. Yoon S. Cho-Chung, from August 1990 through December 1995. Dr. Budillon joined the National Cancer Institute of Naples-Fondazione Pascale, in 1996. He is currently the Chief of Experimental Pharmacology Unit. Dr. Budillon is the author of more than 100 papers published in peer-reviewed journals and have a patent on a cancer diagnostic tool (H-Index Google Scholar: 37). Since 1991, he has published several papers on the molecular mechanism of novel anticancer drugs and on the potential combination approaches between conventional and targeted based drugs. In recent years, Dr. Budillon research focused on histone deacetylase inhibitors (HDACi), a class of drugs studied in some models of solid tumors where the limits of conventional therapies, especially in advanced disease, stimulate the research on innovative approaches. He published studies on the mechanism underlying the synergistic effect between HDACi and several agents such as EGFR Tyrosine Kinase Inhibitors (TKIs), fluoropyrimidines, cisplatin, topoisomerase inhibitors, radiotherapy and others, launching ongoing clinical studies with these approaches. He also launched a recent program of repositioning of drugs commonly used for the treatment of diseases other than cancer, such as valproic acid, simvastatin, metformin and aspirin, in combination with conventional approaches. Dr. Budillon is also interested in the identification of new predictive biomarkers for anti-angiogenic drugs and he is currently involved in the standardization of phenotypic characterization of circulating endothelial (CECs) and progenitors (CEPs) cells in healthy donors and cancer patients undergoing treatment with the anti-VEGF antibody bevacizumab. Other scientific interests are related with proteomic approach in defining new molecular diagnostic and therapeutic targets as well as with pharmacogenetics. Selected Publications [1]
Budillon A, Tagliaferri P, Caraglia M, Torrisi MR, Normanno N, Iacobelli S, Palmieri G, Stoppelli MP, Frati L, Bianco AR. Upregulation of epidermal growth factor receptor induced by -interferon in human epidermoid cancer cells. Cancer Res 1991; 51: 1294-9. [2] Budillon A, Cereseto A, Kondrashin A, Nesterova M, Merlo G, Clair T, Cho-Chung YS. Point mutation of the autophosphorylation site or in the nuclear location signal causes protein kinase A RII beta regulatory subunit to lose its ability to revert transformed fibroblasts. Proc Natl Acad Sci 1995; 92: 10634-8. [3] Budillon A, Di Gennaro E, Caraglia M, Barbarulo D, Abbruzzese A, Tagliaferri P. 8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor. Brit J Cancer 1999; 81: 1134-41. [4] Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003; 195(1): 139-50. [5] Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN- in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2006; 12: 617-25. [6] Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009; 8: 3075-87. [7] Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano A, De Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Brit J Cancer 2010; 103: 1680-91. [8] Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Phys 2011; 226: 2378-90. [9] Bianchi L, Bruzzese F, Leone A, Gagliardi A, Puglia M, Di Gennaro E, Rocco M, Gimigliano A, Pucci B, Armini A, Bini L, Budillon A. Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. Proteomics 2011; 11: 3725-42. [10] Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis 2013; 4: e641. [11] Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis 2013; 4: e878. [12] Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Barberio MT, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic Acid - short RadioTherapy - Rectum 3rd Trial). BMC Cancer 2014; 14: 875.
